4 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.3%) at 13,114 as of Friday, Dec. 7, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,438 issues advancing vs. 1,420 declining with 156 unchanged.

The Health Services industry currently sits up 0.8% versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Intuitive Surgical ( ISRG), up 0.8%. Top gainers within the industry include WellCare Health Plans ( WCG), up 3.9%, HCA Holdings ( HCA), up 2.1% and Humana ( HUM), up 1.5%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Fresenius Medical Care Corporation ( FMS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Fresenius Medical Care Corporation is down $0.53 (-1.5%) to $34.81 on light volume Thus far, 53,127 shares of Fresenius Medical Care Corporation exchanged hands as compared to its average daily volume of 164,500 shares. The stock has ranged in price between $34.67-$34.82 after having opened the day at $34.79 as compared to the previous trading day's close of $35.34.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides products and services for the treatment of end-stage renal disease worldwide. The company owns and operates dialysis clinics that provide dialysis treatment, and related laboratory and diagnostic services. Fresenius Medical Care Corporation has a market cap of $10.6 billion and is part of the health care sector. The company has a P/E ratio of 19.9, above the S&P 500 P/E ratio of 17.7. Shares are up 3.3% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Fresenius Medical Care Corporation a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fresenius Medical Care Corporation Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

3. As of noon trading, PerkinElmer ( PKI) is down $0.44 (-1.4%) to $30.45 on average volume Thus far, 423,073 shares of PerkinElmer exchanged hands as compared to its average daily volume of 760,700 shares. The stock has ranged in price between $30.38-$31.04 after having opened the day at $31.02 as compared to the previous trading day's close of $30.89.

PerkinElmer, Inc. provides technology, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates in two segments, Human Health and Environmental Health. PerkinElmer has a market cap of $3.6 billion and is part of the health care sector. The company has a P/E ratio of 3110.0, above the S&P 500 P/E ratio of 17.7. Shares are up 55.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate PerkinElmer a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates PerkinElmer as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full PerkinElmer Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

2. As of noon trading, Cooper Companies ( COO) is down $1.30 (-1.4%) to $92.56 on heavy volume Thus far, 361,361 shares of Cooper Companies exchanged hands as compared to its average daily volume of 394,900 shares. The stock has ranged in price between $91.11-$93.51 after having opened the day at $92.00 as compared to the previous trading day's close of $93.85.

The Cooper Companies, Inc. engages in the provision of medical devices for healthcare professionals worldwide. Cooper Companies has a market cap of $4.5 billion and is part of the health care sector. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are up 33.1% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Cooper Companies a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Cooper Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cooper Companies Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

1. As of noon trading, Boston Scientific ( BSX) is down $0.04 (-0.7%) to $5.55 on heavy volume Thus far, 10.5 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 13.6 million shares. The stock has ranged in price between $5.51-$5.63 after having opened the day at $5.62 as compared to the previous trading day's close of $5.59.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $7.6 billion and is part of the health care sector. Shares are up 4.3% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Boston Scientific a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Boston Scientific Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space